Waldenström’s Macroglobulinemia Clinical Trial Remains on Track Despite Pandemic
Despite the COVID-19 global pandemic, the Phase 1b clinical trial of mavorixafor in patients with Waldenström’s macroglobulinemia remains on track, X4 Pharmaceuticals, Inc announced in a press release.
The Phase 1b multi-center, open-label, dose-escalation clinical trial is assessing the safety and tolerability of mavorixafor in combination with ibrutinib, as well as its effectiveness.
Data from the trial is expected to be released in the second half of 2020.
“During these challenging and unprecedented times, our thoughts are with everyone affected by the COVID-19 pandemic,” said Paula Ragan, PhD, President and Chief Executive Officer of X4 Pharmaceuticals in the release. “Here at X4, we continue our efforts to advance our lead product candidate, mavorixafor, through clinical development. As presented at our analyst day in April, we recently completed market research that enabled us to update and increase our estimates on the U.S. prevalence of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis, or WHIM, syndrome, our lead indication for mavorixafor.”
Read the full press release here.